Blog
RSS FeedPosted by Michael Wonder on 23 Sep 2019
Pembrolizumab in metastatic NSCLC: now added benefit for subpopulations
19 September 2019 - After a methodological uncertainty has been resolved, analyses on overall survival are now usable ...
Posted by Michael Wonder on 19 Sep 2019
5 people setting EU drug prices
19 September 2019 - Politic’s guide to the policy makers debating how to calculate the cost of cures. ...
Posted by Michael Wonder on 16 Sep 2019
HTA in the European Union: osteoporosis screening without proof of benefit
16 September 2019 - For the first time, an IQWiG team is in charge of assessing health technology for the ...
Posted by Michael Wonder on 11 Sep 2019
Germany may have the answer for reducing drug prices
11 September 2019 - American lawmakers attempting to stem spiraling drug costs might find inspiration in Germany, where the government’s ...
Posted by Michael Wonder on 05 Aug 2019
Dacomitinib in advanced lung cancer: variety of disadvantages lifts survival advantage
1 August 2019 - Prolonged survival is sometimes accompanied by severe side effects, symptom and quality of life deterioration ...
Posted by Michael Wonder on 31 Jul 2019
Ezetimibe reduces the risk of heart attacks and strokes
26 July 2019 - Added to existing statin therapy, ezetimibe is preventative in patients with CHD and acute coronary syndrome. ...
Posted by Michael Wonder on 18 Jul 2019
Evaluation of ethical analyses in seven reports from the European Network for Health Technology Assessment
16 July 2019 - Ethics has been considered among the core domains of health technology assessment, but there are still ...
Posted by Michael Wonder on 13 Jul 2019
Early benefit assessment reveals weaknesses in the development of new drugs
11 July 2019 - Analysis of 216 AMNOG assessments in the BMJ / Proposals for more targeted drug development ...
Posted by Michael Wonder on 11 Jul 2019
New drugs: where did we go wrong and what can we do better?
10 July 2019 - More than half of new drugs entering the German health care system have not been shown to ...
Posted by Michael Wonder on 10 Jul 2019
Biomarker-based cancer diagnostics: German pricing regulator sets high validation and reimbursement standards for novel diagnostic methods
10 July 2019 - On 20 June 2019, for the first time, the German Federal Joint Committee (G-BA), made the resolution ...
Posted by Michael Wonder on 08 Jul 2019
Report calls for European funding reform for gene therapies
8 July 2019 - New payment models, dedicated investment, and better health technology assessment are among a raft of changes ...
Posted by Michael Wonder on 08 Jun 2019
UK, Germany, dissociate from WHO drug pricing resolution
8 June 2019 - The passage of a landmark resolution on improving the transparency of markets for medicines at the latest ...
Posted by Michael Wonder on 20 May 2019
Europe responding to gene therapy challenge, but picture remains fragmented
20 May 2019 - Germany, Italy and England using outcomes-based deals. ...
Posted by Michael Wonder on 15 May 2019
Nivolumab and ipilimumab: drug combination has added benefit in advanced renal cell carcinoma
15 May 2019 - There are no serious disadvantages in terms of overall survival. ...
Posted by Michael Wonder on 02 May 2019
Apalutamide in prostate cancer: indication of significant added benefit
2 May 2019 - Study shows significant slowing of symptomatic progression. ...